Heron Therapeutics, Inc. is a company I see potential value in. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, SUSTOL® (granisetron) and CINVANTI® (aprepitant). HTX-011 (bupivacaine and meloxicam) is their investigational product that has a Prescription Drug User Fee Act (PDUFA) date of 30 April 2019.